Brief: Xvivo Perfusion Q3 EBITDA ex-items effecting comparability up by 22 pct
Oct 27 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* Q3 net sales 31.7 million Swedish crowns ($3.56 million) versus 26.6 million crowns year
ago
* Q3 EBITDA ex-items effecting comparability up by 22 percent to 5.4 million crowns
Source text for Eikon: ID:nWkrjA1074
Further company coverage: XVIVO.ST
($1 = 8.9092 Swedish crowns)
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength